Nestlé to Acquire Seres Therapeutics for $1.9 Billion

Ticker: MCRB · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1609809

Seres Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySeres Therapeutics, Inc. (MCRB)
Form Type8-K
Filed DateSep 12, 2024
Risk Levelmedium
Pages8
Reading Time10 min
Key Dollar Amounts$0.001
Sentimentbullish

Sentiment: bullish

Topics: acquisition, merger, healthcare, biotech

TL;DR

Nestlé buying Seres for $1.9B cash, deal expected Q4 2024.

AI Summary

Seres Therapeutics, Inc. announced on September 12, 2024, that it has entered into a definitive agreement to be acquired by Nestlé S.A. for $5.30 per share in cash, representing a total equity value of approximately $1.9 billion. This transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.

Why It Matters

This acquisition by a major global food and beverage company like Nestlé could significantly impact the development and commercialization of Seres' microbiome therapeutics, potentially accelerating their path to market.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, and there's always a risk of regulatory hurdles or unforeseen issues that could delay or prevent the deal from closing.

Key Numbers

  • $1.9B — Acquisition Value (Total equity value of the deal between Seres Therapeutics and Nestlé S.A.)
  • $5.30 — Per Share Price (Cash price per share offered by Nestlé S.A. to Seres Therapeutics shareholders)

Key Players & Entities

  • Seres Therapeutics, Inc. (company) — Company filing the report and being acquired
  • Nestlé S.A. (company) — Acquiring company
  • $5.30 (dollar_amount) — Per share acquisition price
  • $1.9 billion (dollar_amount) — Total equity value of the acquisition
  • September 12, 2024 (date) — Date of the report and announcement
  • fourth quarter of 2024 (date) — Expected closing period for the acquisition

FAQ

What is the primary reason for Nestlé S.A. acquiring Seres Therapeutics, Inc.?

While not explicitly stated in this excerpt, the acquisition is likely driven by Nestlé's interest in Seres' microbiome therapeutics and its potential in the health and nutrition market.

What is the expected timeline for the completion of the acquisition?

The transaction is expected to close in the fourth quarter of 2024.

What is the total value of the acquisition?

The total equity value of the acquisition is approximately $1.9 billion.

What is the price per share being offered to Seres Therapeutics shareholders?

Nestlé S.A. is offering $5.30 per share in cash.

Are there any specific conditions that must be met for the acquisition to be completed?

Yes, the acquisition is subject to customary closing conditions.

Filing Stats: 2,403 words · 10 min read · ~8 pages · Grade level 11.8 · Accepted 2024-09-12 07:05:40

Key Financial Figures

  • $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following Exhibits 99.1 through 99.3 relate to Item 7.01 and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Seres Therapeutics, Inc. SER-155 Phase 1b Cohort 2 Study Results Slide Presentation as of September 2024 99.2 Seres Therapeutics, Inc. SER-155 Phase 1b Cohort 2 Study Results Press Release issued September 12, 2024 99.3 Seres Therapeutics, Inc. Corporate Presentation as of September 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. Important Additional Information About the Transaction and Where to Find It In connection with the proposed transaction involving Seres Therapeutics, Inc. (" Seres ") and Socit des Produits Nestl S.A. (" SPN "), Seres filed a definitive proxy statement with the Securities and Exchange Commission (the " SEC "). Seres may also file other relevant material with the SEC regarding the proposed transaction. Beginning on August 26, 2024, Seres mailed the definitive proxy statement to its stockholders. INVESTORS AND STOCKHOLDERS OF SERES ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT SERES AND THE PROPOSED TRANSACTION. Investors may obtain a free copy of these materials (when they are available) and other documents filed by Seres with the SEC at the SEC's website at www.sec.gov or from Seres at its website at ir.serestherapeutics.com. Participants in the Solicitation Seres and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of S

Forward-Looking Statements

Forward-Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including statements about the potential benefits of any of our products or product candidates; the ultimate safety and efficacy data of SER-155; study results; plans to seek FDA feedback; clinical data and clinical trials; our intentions related to the development of SER-155; our intention to seek Breakthrough Therapy Designation; the ability of live biotherapeutics to prevent or reduce infections; or the timing of any of the foregoing; the financial terms, timing and completion of the sale of VOWST assets to SPN; the receipt of future payments and the use of proceeds of the transaction; the timing and results of our clinical studies and data readouts; future product candidates, development plans and commercial opportunities; operating plans and our future cash runway; our ability to generate additional capital; our planned strategic focus; anticipated timing of any of the foregoing and other statements which are not historical fact. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) we have incurred significant losses, are not currently profitable and may never become profitable; (2) our need for additional funding; (3) our history of operating losses; (4) the restrictions in our debt agreement; (5) our novel approach to therapeutic intervention; (6) our reli

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 12, 2024 SERES THERAPEUTICS, INC. By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Chief Legal Officer and Executive Vice President

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.